Impact of cytochrome P-450 3A4 enzyme/P-glycoprotein inducing antiseizure medications on direct oral anticoagulant therapy
No excess risk of thrombosis during concomitant use of DOACs with CYP3A4/P-gp inducing antiseizure medications compared to use with gabapentin was identified. Further research is needed to confirm an association with excess all-cause mortality.
Authors
- Rita L. Hui (ORCID: https://orcid.org/0000-0003-0014-2431)
- Madalyn Kuhlenberg
- Fang Niu (ORCID: https://orcid.org/0009-0004-3439-7410)
- Nathan P. Clark (ORCID: https://orcid.org/0000-0002-9289-7710)
- Thomas Delate (ORCID: https://orcid.org/0000-0002-6530-8415)
- Sean M. McNary
- Lucia F. Basilio
Institutions
- Kaiser Permanente (US)
- Kaiser Permanente Fontana Medical Center (US)
Publication Details
- Journal
- Blood Coagulation & Fibrinolysis
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1097/mbc.0000000000001342
- Citations
- 2
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.78